Elixir Pharmaceuticals, Inc.

There’s a description of the motivations of angel investors in a 1996 Journal of Business Review paper that is still often cited. One motivation is altruism, a desire to give back to society. Anothe

In an efficient partnering world, the collapse of the financing market should have decreased deal prices while increasing their volume. It's done the former, but not the latter. By Roger Longman and C

In the current biotech economy, corporate venture groups are playing an increasingly important role in the funding of early-stage start-ups. As their cachet grows, these outfits can drive harder barga

by Mark L. Ratner Pathway-oriented platforms are rare, and dealmaking around them can be complicated. But Sirtris has pulled it off. The unique nature of Sirtris’ broad but target-specific platform ar